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Proteoglycan-4 regulates fibroblast to
myofibroblast transition and expression of
fibrotic genes in the synovium
Marwa Qadri1,2, Gregory D. Jay3, Ling X. Zhang3, Holly Richendrfer3, Tannin A. Schmidt4 and Khaled A. Elsaid1*
Abstract
Background: Synovial tissue fibrosis is common in advanced OA with features including the presence of stress
fiber-positive myofibroblasts and deposition of cross-linked collagen type-I. Proteoglycan-4 (PRG4) is a mucinous
glycoprotein secreted by synovial fibroblasts and is a major component of synovial fluid. PRG4 is a ligand of the
CD44 receptor. Our objective was to examine the role of PRG4-CD44 interaction in regulating synovial tissue fibrosis
in vitro and in vivo.
Methods: OA synoviocytes were treated with TGF-β ± PRG4 for 24 h and α-SMA content was determined using
immunofluorescence. Rhodamine-labeled rhPRG4 was incubated with OA synoviocytes ± anti-CD44 or isotype control
antibodies and cellular uptake of rhPRG4 was determined following a 30-min incubation and α-SMA expression
following a 24-h incubation. HEK-TGF-β cells were treated with TGF-β ± rhPRG4 and Smad3 phosphorylation was
determined using immunofluorescence and TGF-β/Smad pathway activation was determined colorimetrically. We
probed for stress fibers and focal adhesions (FAs) in TGF-β-treated murine fibroblasts and fibroblast migration was
quantified ± rhPRG4. Synovial expression of fibrotic markers: α-SMA, collagen type-I, and PLOD2 in Prg4 gene-trap
(Prg4GT) and recombined Prg4GTR animals were studied at 2 and 9months of age. Synovial expression of α-SMA and
PLOD2 was determined in 2-month-old Prg4GT/GT&Cd44−/− and Prg4GTR/GTR&Cd44−/− animals.
Results: PRG4 reduced α-SMA content in OA synoviocytes (p < 0.001). rhPRG4 was internalized by OA synoviocytes via
CD44 and CD44 neutralization attenuated rhPRG4’s antifibrotic effect (p < 0.05). rhPRG4 reduced pSmad3 signal in HEK-
TGF-β cells (p < 0.001) and TGF-β/Smad pathway activation (p < 0.001). rhPRG4 reduced the number of stress fiber-
positive myofibroblasts, FAs mean size, and cell migration in TGF-β-treated NIH3T3 fibroblasts (p < 0.05). rhPRG4
inhibited fibroblast migration in a macrophage and fibroblast co-culture model without altering active or total TGF-β
levels. Synovial tissues of 9-month-old Prg4GT/GT animals had higher α-SMA, collagen type-I, and PLOD2 (p < 0.001)
content and Prg4 re-expression reduced these markers (p < 0.01). Prg4 re-expression also reduced α-SMA and PLOD2
staining in CD44-deficient mice.
Conclusion: PRG4 is an endogenous antifibrotic modulator in the joint and its effect on myofibroblast formation is
partially mediated by CD44, but CD44 is not required to demonstrate an antifibrotic effect in vivo.
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Background
Osteoarthritis (OA) is the most prevalent type of muscu-
loskeletal disorder in patients 60 years or older [1–3].
OA is a leading cause of pain and disability and patients
with symptomatic knee OA are at an increased risk of
all-cause mortality [4–6]. The etiology of OA is complex
where joint trauma, obesity, and genetics, among other
risk factors, contribute to disease development [7–10].
OA affects the whole joint with manifestations that
include degeneration of articular cartilage and the me-
niscus, abnormal bone remodeling, and synovial inflam-
mation [11–13]. Macroscopic evidence of synovial
inflammation or synovitis is a common finding in up to
74% of patients with knee OA of different grades and
95% of patients with moderate to severe OA [14–16].
OA synovitis is likely caused by an innate immune re-
sponse, mediated by the toll-like receptors 2 and 4
(TLR2 and TLR4) in the synovium, and resultant expres-
sion of inflammatory cytokines, chemokines, and matrix-
degrading enzymes [17–21]. The extent of synovitis is a
strong predictor of OA progression across multiple stud-
ies, and therefore treating synovial inflammation is a po-
tentially important target for therapeutic intervention,
especially during the early stage of OA [14, 22–27].
The normal synovium is composed of a cellular in-
timal layer and a subintimal connective tissue layer [14,
28]. The intimal layer is usually 1–4 cells in thickness
with two types of cells: type A macrophages and type B
synovial fibroblasts, with macrophages making up a
smaller percentage of cells in the intimal layer of the
healthy synovium [28]. Synovial fibroblasts synthesize
hyaluronic acid (HA), a glycosaminoglycan, and
proteoglycan-4 (PRG4), a mucinous glycoprotein, which
are major components of synovial fluid (SF) with im-
portant roles in joint lubrication [29, 30]. In synovitis,
synovial membranes become hyperplastic with increased
accumulation of macrophages and other inflammatory
cells, along with subintimal fibrosis and angiogenesis
[13, 14, 31]. Synovial fibrosis can be considered a mal-
adaptive healing response to chronic synovitis which is
characterized by the upregulation of collagen type-I ex-
pression, fibroblast transition to a myofibroblast-like
phenotype through de novo expression of alpha smooth
muscle actin (α-SMA) and enhanced migratory behavior,
and upregulation of procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 2 (PLOD2) leading to accumulation of
cross-linked collagen in the synovium [32–34]. These
pathological changes are induced in the OA synovium
by transforming growth factor beta (TGF-β1) and its as-
sociated signaling pathways [35, 36]. Synovial fibrosis
also contributes to joint pain and stiffness observed in
advanced OA [31, 37].
In a recent study, we demonstrated that increasing
intracellular adenosine 3′, 5′-cyclic monophosphate
(cAMP), using forskolin, reduced collagen type-I, PLOD2,
and α-SMA expression in TGF-β-stimulated osteoarthritic
fibroblast-like synoviocytes (OA FLS) [38]. Associated
with this antifibrotic effect was an increase in HA and
PRG4 production by OA FLS, whereby native synovial hu-
man PRG4 reduced procollagen type-I level in OA FLS
[38]. Furthermore, synoviocytes from Prg4 null mice dis-
played more extensive collagen type-I staining com-
pared to synoviocytes from Prg4 competent mice [38].
In a separate study, we have also shown that PRG4 is
a ligand for the HA receptor, CD44 [39]. We have
also reported that PRG4-CD44 interaction inhibited
interleukin-1 beta (IL-1β) induced OA FLS prolifera-
tion and expression of matrix-degrading enzymes
[40], via the inhibition of nuclear factor kappa b (NF-
κB) nuclear translocation mediated by blocking inhibi-
tory kappa b (IκB) degradation [40].
It remains unknown whether PRG4 has a role in regu-
lating fibroblast to myofibroblast transition and associated
cell migration in the fibrotic synovium. Furthermore, it is
yet to be determined whether PRG4 regulates synovial fi-
brosis in vivo and whether this role is due to its inter-
action with the CD44 receptor. Using recombinant
human proteoglycan-4 (rhPRG4), we aimed to study the
role of PRG4 in regulating fibroblast to myofibroblast
transition and modulating fibroblast migration in re-
sponse to exogenous TGF-β or co-incubation with
lipopolysaccharide (LPS) stimulated macrophages. We
also studied the role of PRG4-CD44 interaction, and
more specifically CD44-mediated cellular uptake of
PRG4, in the regulation of myofibroblast formation
in vitro and progression of synovial fibrosis in vivo.
We hypothesized that PRG4 regulates fibroblast to
myofibroblast transition and prevents synovial fibrosis
in a CD44-dependent manner.
Methods
Impact of PRG4 and HA treatments on ACTA2 expression,
α-SMA immunostaining, and stress fiber formation in
osteoarthritic fibroblast-like synoviocytes (OA FLS) and
the role of CD44 in mediating the effect of rhPRG4 in
TGF-β-stimulated OA FLS
OA FLS (Cell Applications, USA) were isolated from
synovial tissues from de-identified patients undergoing
knee replacement surgery (n = 4; 2 males and 2 females;
62–69 years old). Cells were received in their second
passage and were cultured as previously described [20].
OA FLS were used between the 3rd and 6th passages to
avoid alterations in gene expression pattern and cell pro-
liferation rate [41]. OA FLS (300,000 cells/well) in
serum-free DMEM media were treated with recombin-
ant human TGF-β1 (R&D Systems, USA) (1 ng/mL) ±
native human synovial PRG4 (apparent mol mass 280
kDa as a monomer; 100 μg/mL) [42] or high-molecular
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weight hyaluronic acid (HA; ~ 1200 kDa; R&D Systems;
100 μg/mL) for 24 h. RNA isolation, cDNA synthesis,
and quantitative PCR were performed as previously de-
scribed [38]. The cycle threshold (Ct) value of α-SMA
(ACTA2) was normalized to the Ct value of GAPDH in
the same sample, and the relative expression was calcu-
lated using the 2−ΔΔCt method [43]. All primers and
probes utilized in our study are commercially available
(Thermo Fisher Scientific, USA).
Assessment of α-SMA content in OA FLS was con-
ducted using immunofluorescence and determination
of corrected total cell fluorescence (CTCF) using a
Nikon E600 fluorescence microscope. OA FLS (200,
000 cells/well) were cultured on collagen type-I-
coated 22 mm glass coverslips for 48 h in DMEM
medium + 10% fetal bovine serum (FBS). Cells were
treated with TGF-β1 (1 ng/mL) ± PRG4 or HA
(100 μg/mL for both treatments) for 48 h in serum-
free DMEM medium. Subsequently, cells were fixed
in 10% neutral buffered formalin for 15 min and
washed twice with phosphate-buffered saline (PBS).
Cells were permeabilized using 0.01% Triton X-100 in
PBS and blocked using 2% bovine serum albumin
(BSA; Sigma-Aldrich, USA) in PBS for 2 h at room
temperature. Probing for α-SMA was performed using
FITC-conjugated anti-α-SMA antibody (1:100 dilution;
Abcam, USA) and counterstained using Alexa Fluor
594-conjugated anti-α-tubulin antibody (1100 dilution:
Abcam) overnight at 4 °C. Following washing with
PBS, cells were mounted on DAPI mounting shield
(Abcam) and CTCF was quantified using 4 different
fields per slide and mean CTCF was calculated. The
presence of stress fibers in OA FLS was also
evaluated.
Recombinant human PRG4 (rhPRG4; apparent mol
mass 240 kDa) is an endotoxin-free full-length prod-
uct produced by CHO-M cells (Lubris, Framingham,
USA) [44]. Rhodamine labeling of rhPRG4 was per-
formed using the Pierce NHS-Rhodamine Antibody
Labeling Kit (Thermo Fisher Scientific). OA FLS (200,
000 cells/well) were cultured on collagen type-I-
coated cover slips and incubated with rhodamine-
rhPRG4 (25 μg/mL) ± anti-CD44 or isotype control
(IC) antibodies (2 μg/mL for both antibodies; Abcam)
for 30 min. Cells were pre-incubated with the anti-
bodies for 1 h prior to rhPRG4 addition. Subse-
quently, cells were washed twice with PBS and
mounted on DAPI mounting media and CTCF was
quantified as described above. In another set of ex-
periments, OA FLS (300,000 cells/well) were treated
with TGF-β1 (1 ng/mL) ± rhPRG4 (100 μg/mL) ±
anti-CD44 or IC antibodies (2 μg/mL for both anti-
bodies) for 24 h followed by determination of ACTA2
expression as described above.
CD44-dependent uptake of rhPRG4, Smad3
phosphorylation, and regulation of TGF-β/Smad pathway
activation in TGF-β-stimulated HEK Blue-TGF-β cells
HEK Blue-TGF-β is an engineered reporter cell line pro-
duced by transfecting human embryonic kidney (HEK)
cells with TGF-β receptor 1 (TGF-β R1), Smad3, and
Smad4 genes (Invivogen, USA). TGF-β1-treatment results
in phosphorylation of Smad3 (pSmad3) and Smad4
(pSmad4), translocation to the nucleus and expression of
secreted alkaline phosphatase (SEAP). The activity of
SEAP can be detected colorimetrically in media superna-
tants using a specific substrate (Quanti Blue) at 620–655
nm (Invivogen). HEK-TGF-β cells (500,000) were plated
onto sterile chamber slides and incubated with
rhodamine-rhPRG4 (25 μg/mL) for 1 h ± anti CD44 or IC
antibodies (2 μg/mL for both antibodies). Cells were pre-
incubated with the antibodies for 1 h prior to rhPRG4
addition. Subsequently, cells were washed with PBS and
intracellular CTCF was determined as described above. In
another set of experiments, rhodamine-labeled rhPRG4
(25 μg/mL) was incubated with HEK-TGF-β cells and
CD44 was probed using FITC-conjugated anti-CD44 anti-
body (Abcam) and CD44 (green) and rhPRG4 (red) co-
localization was examined using a confocal microscope.
Immunostaining of pSmad3 was performed using an
anti-Smad3 antibody that detects phosphorylated serine
residues (1:1000 dilution overnight at 4 °C; Abcam).
HEK-TGF-β cells were stimulated with TGF-β1 ±
rhPRG4 (150 μg/mL) for 1 h. Subsequently, cells were
fixed, washed with PBS, and permeabilized as described
above. Following probing with anti-pSmad3 antibody,
cells were washed with PBS and incubated with goat
anti-rabbit IgG (Alexa Fluor 488) (1:1000 dilution for 1 h
at room temperature; Abcam). Cells were subsequently
washed with PBS and the green immunofluorescence
was quantified across all experimental groups. To inves-
tigate the impact of rhPRG4 on TGF-β/Smad pathway
activation, HEK-TGF-β cells (100,000 cells/well) were
cultured in sterile 96-well plates ± TGF-β1 (1 ng/mL) ±
rhPRG4 (50, 100, or 150 μg/mL) for 24 h in Quanti-Blue
media and the 655 nm absorbance intensity was deter-
mined. Data are presented as fold absorbance intensities
across experimental groups normalized to untreated
controls.
TGF-β induction of stress fibers, focal adhesions (FAs) and
cell migration in murine NIH3T3 fibroblasts, comparison
of stress fibers and FAs in Prg4+/+ and Prg−/− synovial
fibroblasts and role of rhPRG4 in regulating fibroblast
migration
Murine fibroblasts (NIH3T3; ATCC; 20,000 cells/well)
were cultured on collagen type-I-coated 22-mm glass
coverslips for 24 h in DMEM supplemented with 10%
bovine calf serum (BCS). NIH3T3 cells were starved in
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DMEM containing 1% BCS for 24 h. Murine fibroblasts
were treated with murine TGF-β1 (1 ng/mL) ± rhPRG4
(200 μg/mL) for 24 h in serum-free DMEM. Subse-
quently, fibroblasts were fixed using neutral buffered for-
malin, washed with PBS, permeabilized using 0.1% triton
X-100, and probed using an anti-α-SMA (marker of
stress fibers; 1:1,000) or anti-vinculin (marker of FA
complex; 1:1,000) overnight at 4 °C. After washing with
PBS, cells were incubated with goat anti-rabbit IgG
(Alexa Fluor® 488) at 1:1000 dilution for 1 h at 4 °C.
Rhodamine-labeled phalloidin (cytoskeleton label; 1:
1000) was added with the secondary antibody. All anti-
bodies were obtained from Abcam. Cells were washed
and mounted with DAPI medium for 2 h and viewed
under a confocal microscope. A blinded investigator
determined the number of stress fiber-positive fibro-
blasts. At least 100 cells over at least 5 different fields
were evaluated, and the percentage of stress fiber-
positive fibroblasts was calculated. Separately, mean
fibroblast cell spread area was determined using the
NIS-Elements imaging software (Nikon). The number
and mean size of FAs per cell were determined using
ImageJ software as previously described [45]. Fibroblast
migration was determined using a scratch assay. A 1000-
μL pipette tip was used to perform a uniform scratch in
the confluent NIH3T3 fibroblast monolayer. TGF-β (1
ng/mL) stimulation was performed for 48 h ± rhPRG4
(200 μg/mL). Subsequently, cells were washed and
stained (Cell Biolabs) and imaged using an all-in-one
fluorescence microscope (Keyence). A region of interest
was defined and scratch widths were determined across
multiple locations. Cell migration was expressed as per-
cent wound closure across different experimental groups
as previously described [46].
The phenotype of Prg4−/− mice is characterized by
synovial membrane hyperplasia, chondrocyte apoptosis,
and cartilage surface fibrillation [47]. The Prg4−/− mouse
colony is maintained by Dr. Gregory Jay at Rhode Island
Hospital (RIH) and is commercially available (stock no.
025737; JAX, USA). The IACUC committee at RIH ap-
proved all animal experiments and all experiments were
performed according to all applicable guidelines and reg-
ulations. Synoviocyte isolation from Prg4−/− and Prg4+/+
synovial tissues was performed as previously described
[38, 39]. Prg4−/− and Prg4+/+ synoviocytes were plated
onto sterile chamber slides (Thermo Fisher Scientific)
and allowed to adhere for 48 h. Subsequently, cells were
stained for α-SMA and vinculin as described above. The
mean size of FAs per cell in Prg4−/− and Prg4+/+ synovio-
cytes was determined as described above. Prg4−/− and
Prg4+/+ synoviocytes were seeded in 6-well plates and a
scratch was performed in the confluent cell monolayer.
Basal synovial fibroblast migration of both genotypes
was quantified over 48 h ± rhPRG4 (200 μg/mL), anti-
CD44 (2 μg/mL), or IC (2 μg/mL) antibodies and
expressed as percent wound closure [46].
Generation of active TGF-β in lipopolysaccharide-
stimulated murine macrophage J774A and NIH3T3
fibroblast co-culture and impact of rhPRG4 treatment on
fibroblast migration
Murine J774A macrophages (ATCC) were cultured in
DMEM medium + 10% FBS. Macrophages (300,000 cells
in DMEM medium + 10% FBS) were stimulated with
lipopolysaccharide (LPS; Invivogen) (5 μg/mL) for 24 h.
Subsequently, murine macrophages were washed five
times with DMEM medium and transferred to the top
chamber of a transwell co-culture system (0.4-μm pore
size; Sigma-Aldrich). Murine NIH3T3 cells were seeded
in the lower chamber of the transwell system and a
scratch was performed as described above. NIH3T3 mi-
gration was determined following a 48-h incubation of
fibroblasts with macrophages in the co-culture system as
described above ± rhPRG4 (200 μg/mL). Active and total
TGF-β media levels were determined using an ELISA
(R&D Systems).
Age-dependent expression of fibrotic markers in synovial
tissues from Prg4GT/GT animals and the role of PRG4/CD44
interaction in modulating synovial fibrosis in vivo
The Prg4 gene-trap (Prg4GT) mouse colony is maintained
by Dr. Gregory Jay at RIH and is commercially available
(stock no. 025740; JAX) [48]. Prg4GT animal is a genetic-
ally engineered PRG4-deficient mouse where the Prg4
expression can be restored via CRE-mediated recombin-
ation [48]. The Prg4GT/GT mouse recapitulates the hall-
mark findings in Prg4−/− mouse, namely synovial tissue
hyperplasia and cartilage surface fibrillations and recom-
bination in 3-week-old animals improved but did not
completely normalize joint pathological findings [48]. In
our studies, recombination (Prg4GTR/GTR) occurred in 3-
week-old animals via intraperitoneal injection of tamoxi-
fen (0.1 mg/g in 100 μL corn oil vehicle) daily for 10
days. We compared gene expression and immunostain-
ing of fibrotic markers: α-SMA, COL1A1 (collagen type-
I), and PLOD2 in 2-month-old Prg4GT/GT, 2-month-old
Prg4GTR/GTR, 9-month-old Prg4GT/GT, and 9-month-old
Prg4GTR/GTR animals. ACTA2, COL1A1, and PLOD2 ex-
pression levels in murine synovial tissues were per-
formed as previously described [38]. Tissues from each
three consecutive mice were pooled and underwent
RNA isolation, generating five pooled samples in each
experimental group. Separately, animal joints (n = 5 in
each group) underwent decalcification and paraffin-
embedded sectioning as previously described [48]. Im-
munostaining of synovial tissues was performed using
primary antibodies against α-SMA, COL1A1, or PLOD2
(1:1000 dilutions performed overnight at 4 °C) (All
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antibodies were purchased from Abcam). Subsequently,
sections were washed and incubated with goat anti-
rabbit IgG (Alexa Fluor 488) (1:1000 dilution) for 1 h
and fluorescence intensities (expressed as lumens per
square millimeter) were quantified using a fluorescence
microscope.
To appreciate the significance of PRG4 and CD44
interaction in the context of fibrotic markers’ expression
in the synovium, Prg4GT/GT animals were crossed with
Cd44−/− mice (stock no. 005085; JAX) [49] to generate
Cd44−/−&Prg4GT/GT animals. Recombination occurred in
3-week-old animals to generate Cd44−/−&Prg4GTR/GTR
animals as described in the last paragraph. Histological
analyses of joints harvested from 2-month-old animals
(at least 4 animals per group) were performed as de-
scribed above, using Cd44+/+&Prg4GT/GT animals from
the same litters as controls. We probed synovial tissues
for the following fibrotic markers: α-SMA and PLOD2
using specific primary antibodies (1:1000 dilutions)
followed by goat anti-rabbit IgG (Alexa Fluor 488) and
quantitation of fluorescence intensities (expressed as lu-
mens per square millimeter) as described above.
Statistical analyses
Target gene expression was statistically evaluated by
comparing ΔCt (Ct value of target gene −Ct value of
GAPDH in the same sample) values of different experi-
mental groups. Statistical significance comparing two
groups or multiple groups with parametric data was
assessed by Student’s t test or ANOVA followed by post
hoc multiple comparisons (Tukey’s post hoc test). Statis-
tical significance comparing two groups or multiple
groups with nonparametric data was assessed by rank
sum test or ANOVA on the ranks. A p value of < 0.05
was considered statistically significant. Data are pre-
sented as scatter plots with mean and standard devia-
tions highlighted.
Results
PRG4 reduced ACTA2 expression and stress fiber
formation in osteoarthritic fibroblast-like synoviocytes
(OA FLS) and CD44 was involved in the uptake of rhPRG4
by OA FLS, whereas rhPRG4-CD44 interaction affected
ACTA2 expression in response to TGF-β
PRG4 and HA treatments demonstrated equivalent effi-
cacies in reducing ACTA2 expression in OA FLS
(Fig. 1a). Both treatments reduced ACTA2 expression
compared to the positive control TGF-β1 (p < 0.001 for
TGF-β1 + PRG4 or TGF-β1 + HA against TGF-β1
alone). In addition to reducing ACTA2 expression,
PRG4 reduced α-SMA content in OA FLS (p < 0.001
versus TGF-β1 alone; Fig. 1c). A similar effect was also
observed for HA treatment (p < 0.001 versus TGF-β1
alone; Fig. 1c). The effect of PRG4 was biologically
significant with approximately 52% reduction in mean α-
SMA immunofluorescence compared to TGF-β1 alone.
In addition to reducing α-SMA in OA FLS, PRG4, and
HA treatments prevented the formation of stress fibers
in OA FLS in response to TGF-β1 stimulation (Fig. 1b).
rhPRG4 was rapidly internalized by OA FLS and the
mechanism of its internalization was related to its inter-
action with CD44. This was illustrated by a reduction in
OA FLS CTCF with an anti-CD44 treatment (Fig. 1d, e).
Neutralization of CD44 receptor did not completely
block rhPRG4 uptake by OA FLS (Fig. 1e). Alternatively,
treatment with an IC antibody did not alter rhPRG4’s
uptake by OA FLS (p > 0.05; Fig. 1e). Inhibition of
ACTA2 expression by rhPRG4 was attenuated by pre-
incubation with an anti-CD44 antibody (p < 0.05 for
TGF-β1 + rhPRG4 + anti-CD44 versus TGF-β1 +
rhPRG4; Fig. 1f). In contrast, IC antibody treatment did
not alter the magnitude of reduction in ACTA2 expres-
sion observed with rhPRG4 (Fig. 1f).
CD44 receptor facilitated rhPRG4 uptake by HEK-TGFβ
cells and rhPRG4 inhibited TGF-β1/Smad pathway
activation
Representative images demonstrate intracellular red fluor-
escence following the incubation of rhodamine-labeled
rhPRG4 with HEK-TGFβ cells (Fig. 2a). Antibody-
mediated CD44 receptor neutralization reduced the inten-
sity of red fluorescence, indicative of reduced rhPRG4
uptake into HEK-TGFβ cells (p < 0.001 vs. rhPRG4 alone;
Fig. 2a, b). This effect was specific to CD44 receptor, as a
non-specific IC antibody pre-incubation did not alter the
extent of rhPRG4 uptake into HEK-TGFβ cells (p > 0.05;
Fig. 2a, b). Further evidence of CD44 involvement in
rhPRG4 uptake by HEK-TGFβ cells is provided by the
intracellular co-localization of rhPRG4 (red) and CD44
(green) as shown by arrows (yellow color) (Fig. 2a). TGF-
β1 stimulation resulted in Smad3 phosphorylation as
shown in representative images (Fig. 2c). Intense green
fluorescence in TGF-β1-stimulated HEK-TGF-β cells indi-
cated the formation of pSmad3. rhPRG4 treatment re-
duced mean pSmad3 staining intensity subsequent to
TGF-β1 stimulation (p < 0.001; Fig. 2d). In addition,
rhPRG4 treatment dose-dependently reduced TGF-β1/
Smad pathway activation as shown by a reduction in the
formation of SEAP colored product (p < 0.05 for 100 and
150 μg/mL concentrations versus TGF-β1 alone; Fig. 2e).
TGF-β induced the formation of stress fibers and FAs in
murine fibroblast NIH3T3 cells resulting in enhanced cell
migration, and these effects were reduced with rhPRG4
treatment
Representative images highlight that murine TGF-β in-
duced the formation of stress fibers and vinculin expres-
sion and thus FAs in NIH3T3 cells (Fig. 3a). TGF-β
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increased the percentage of stress fiber-positive NIH3T3
cells by ~ 5-fold (p < 0.001 against control cells; Fig. 3b)
and increased mean cell spread area by ~ 2-fold (p <
0.001 against control cells; Fig. 3c). rhPRG4 treatment
reduced the percentage of stress fiber-positive NIH3T3
cells (p < 0.001; Fig. 3b) and mean cell spread area (p <
0.001; Fig. 3c) to control levels. TGF-β increased the
number of FAs in NIH3T3 cells by ~ 4-fold (p < 0.001;
Fig. 3d), and the mean size of FAs per cell by ~ 2-fold
(p < 0.05; Fig. 3e). Likewise, rhPRG4 treatment reduced
the number of FAs (p < 0.001; Fig. 3d) and mean FA size
(p < 0.05; Fig. 3e) to control levels. A functional outcome
of TGF-β induced stress fiber and FAs formation was
the enhanced migration of NIH3T3 fibroblasts (Fig. 3f).
rhPRG4 reduced TGF-β-stimulated NIH3T3 fibroblast
migration (p < 0.001; Fig. 3g) while rhPRG4 alone did
not change basal NIH3T3 fibroblast migration (p > 0.05
against control; Fig. 3g).
Lack of Prg4 expression in murine synovial fibroblasts
was associated with increased formation of stress fibers,
mean FA size, and enhanced basal cell migration, which
was reduced by rhPRG4 or anti-CD44 antibody
treatments
Representative images demonstrate enhanced α-SMA and
vinculin staining in Prg4−/− synoviocytes compared to
Prg4+/+ synoviocytes (Fig. 4a). The mean size of FAs was ~
2-folds higher in Prg4−/− synoviocytes compared to Prg4+/+
Fig. 1 Impact of proteoglycan-4 (PRG4) and high-molecular weight hyaluronic acid (HA) treatments on TGF-β1-induced alpha smooth muscle
actin (α-SMA) expression (ACTA2), production and stress fiber formation in fibroblast-like synoviocytes isolated from patients with OA (OA FLS)
undergoing knee replacement surgery and CD44-dependent uptake of rhodamine-labeled recombinant human PRG4 (rhPRG4) into OA FLS and
associated regulation of ACTA2 expression. OA FLS were treated with TGF-β1 (1 ng/mL) ± rhPRG4 (~ 240 kDa) or HA (~ 1200 kDa) (100 μg/mL for
both treatments) for 24 h followed by RNA isolation and qPCR using GAPDH as an internal reference gene. OA FLS were stained with anti-α-SMA
(green) and counterstained for α-tubulin (red) and DAPI (blue). Corrected total cell fluorescence (CTCF) of α-SMA was determined following a 48-
h treatment, and normalized to controls. Rhodamine-labeled rhPRG4 was incubated with OA FLS ± anti-CD44 or isotype control (IC) antibodies for
30 min, and CTFC was quantified. OA FLS were treated with TGF-β1 ± rhPRG4 ± anti-CD44 or IC for 24 h and ACTA2 expression was determined.
Data are presented as a scatterplot with means and standard deviations highlighted utilizing OA FLS from 3 to 4 different patients. *p < 0.001;
***p < 0.05. Scale = 50 μm. a PRG4 and HA reduced ACTA2 expression in OA FLS. b Representative images showing TGF-β1-induced stress fiber
formation in OA FLS (white arrows) and PRG4 or HA treatments prevented their formation. c PRG4 and HA reduced α-SMA CTCF in OA FLS. d
Representative images showing rhodamine-rhPRG4 intracellular localization (white arrows), following incubation with OA FLS. e Co-incubation of
rhPRG4 and anti-CD44 reduced cellular uptake of rhPRG4. f Anti-CD44 antibody co-treatment reduced rhPRG4’s antifibrotic effect in OA FLS
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synoviocytes (p < 0.001; Fig. 4b). Prg4−/− synoviocytes dis-
played enhanced basal migration compared to Prg4+/+ syno-
viocytes (p < 0.01; Fig. 4c, d). rhPRG4 and anti-CD44
antibody treatments reduced Prg4−/− synoviocyte migration
(p < 0.01 for both treatments; Fig. 4d) with no significant dif-
ference between both treatments (p > 0.05).
LPS stimulation of macrophages increased active and
total TGF-β levels in a macrophage and fibroblast co-
culture model, induced fibroblast migration and rhPRG4
treatment reduced fibroblast migration without altering
active or total TGF-β levels
In response to LPS stimulation and co-culture of macro-
phages (M) and fibroblasts (F), active TGF-β levels in
the macrophage and fibroblast co-culture were higher
compared to fibroblasts alone (p < 0.001; Fig. 5a). Cor-
respondingly, total TGF-β levels in the macrophage and
fibroblast co-culture were higher compared to fibroblasts
alone (p < 0.001; Fig. 5a). The increase in active and total
TGF-β levels resulted in enhanced fibroblast migration
in the macrophage and fibroblast co-culture compared
to fibroblasts alone (p < 0.001; Fig. 5b, c). rhPRG4 treat-
ment reduced fibroblast migration in the co-culture
model (p < 0.001; Fig. 5c). The effect of rhPRG4 was not
mediated by an alteration in active or total TGF-β levels,
shown by the lack of differences in active or total TGF-β
concentrations between rhPRG4-treated and untreated
cells (p > 0.05; Fig. 5d).
Fig. 2 CD44-dependent interaction of recombinant human proteoglycan-4 (rhPRG4) with HEK Blue-TGF-β cells and associated modulation of
phosphorylated Smad3 (pSmad3) and TGF-β/Smad signaling pathway. HEK Blue-TGF-β is an engineered cell line produced by transfecting human
embryonic kidney (HEK) cells with TGF-β receptor 1 (TGF-β R1), Smad3, and Smad4 genes. Activation of TGF-β R1 results in expression of secreted
alkaline phosphatase (SEAP) whose activity can be determined colorimetrically. Rhodamine-labeled rhPRG4 was incubated with HEK Blue-TGF-β
cells ± anti-CD44 or isotype control (IC) antibodies and corrected total cell fluorescence (CTCF) was determined. pSmad3 immunocytostaining
was performed using an antibody against pSmad3 and pSmad3 fluorescence intensity was determined. Activity of TGF-β/Smad pathway was
determined colorimetrically. *p < 0.001; **p < 0.01; n.s., non-significant. Scale in a = 40 μm; scale in c = 50 μm. a Representative images showing
rhPRG4 internalization (white arrows) by HEK-TGF-β cells and co-localization with CD44 receptor (white arrows in merged image). b rhPRG4
uptake by HEK-TGF-β cells was reduced by CD44 receptor neutralization. c Representative images showing pSmad3 staining in HEK-TGF-β cells
following TGF-β stimulation (white arrows) ± rhPRG4 treatment. d pSmad3 immunocytostaining was reduced following rhPRG4 treatment. e
rhPRG4 treatment dose-dependently reduced TGF-β/Smad signaling pathway in TGF-β-stimulated HEK-TGF-β cells
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Lack of Prg4 expression resulted in progressive synovial
tissue fibrosis, shown by enhanced α-SMA, collagen type-
I, and PLOD2 production and Prg4 re-expression reduced
synovial tissue fibrosis and this effect was evident in
CD44-deficient mice
Synovial tissues from Prg4GT/GT animals displayed higher
ACTA2, COL1A1, and PLOD2 expression levels compared
to Prg4 wildtype synovia (p < 0.001 for all comparisons;
Fig. 6a, d, g). Interestingly, lack of Prg4 expression resulted
in a greater increase in ACTA2 expression compared to
COL1A1 and PLOD2 (p < 0.001 for all comparisons). The
expression of fibrotic markers in synovial tissues from
Prg4GT/GT animals progressed with age. ACTA2, COL1A1,
and PLOD2 expression levels in 9-month-old Prg4GT/GT
animals were higher than corresponding expression levels
in 2-month-old Prg4GT/GT animals (p < 0.001 for all
comparisons). The regulation of fibrotic gene expression
in the synovium by PRG4 was further confirmed by the
reduction in ACTA2, COL1A1, and PLOD2 expression in
9-month-old Prg4GTR/GTR animals compared to age-
matched Prg4GT/GT animals (p < 0.001 for all compari-
sons). Representative images of synovial tissues stained for
α-SMA, collagen type-I, and PLOD2 proteins are shown
in Fig. 6b, e, and h. There was no significant difference in
mean collagen type-I staining intensity between 2-month-
old Prg4GT/GT and age-matched Prg4GTR/GTR animals (p >
Fig. 3 Impact of recombinant human proteoglycan-4 (rhPRG4) treatment on TGF-β induced stress fiber formation, vinculin expression, and
formation of focal adhesions (FAs) in murine fibroblasts (NIH3T3) and its relationship to cell migration. Stress fiber formation was probed using an
anti-alpha smooth muscle actin (α-SMA) antibody (green) and a blinded investigator evaluated % stress fiber-positive fibroblasts. Vinculin (a
marker of FAs) expression was probed using an anti-vinculin antibody (green) and cells were counterstained using rhodamine-labeled phalloidin
(cytoskeleton label; red). NIH3T3 Fibroblast migration was performed using a scratch assay and the wound closure percentage was determined.
*p < 0.001; **p < 0.01; ***p < 0.05; n.s., non-significant. Scale in a and f = 20 μm; a Representative images showing TGF-β induced stress fiber
formation and vinculin staining (white arrows) in NIH3T3 fibroblasts. b rhPRG4 reduced stress fiber formation in NIH3T3 fibroblasts. c rhPRG4
reduced mean NIH3T3 fibroblast spread area. d rhPRG4 reduced the number of FAs in NIH3T3 fibroblasts. e rhPRG4 reduced the mean size of FAs
in NIH3T3 fibroblasts. f Representative images showing NIH3T3 migration in response to TGF-β ± rhPRG4. g rhPRG4 reduced NIH3T3 migration
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0.05; Fig. 6f). Alternatively, mean α-SMA, collagen
type-I, and PLOD2 staining intensities were lower in
9-month-old Prg4GTR/GTR animals compared to age-
matched Prg4GT/GT animals (p < 0.05 for all compari-
sons; Fig. 6c, f, i).
The contribution of CD44 to PRG4’s effect on α-SMA
and PLOD2 expression was further studied in vivo by
comparing histological staining intensities in synovial
tissues from Cd44+/+&Prg4GT/GT, Cd44−/−&Prg4GT/GT,
and Cd44−/−&Prg4GTR/GTR (Fig. 7). While mean α-SMA
staining intensity trended higher in Cd44−/−&Prg4GT/GT
synovia compared to Cd44+/+&Prg4GT/GT synovia, this
increase did not reach statistical significance (p = 0.16).
Mean α-SMA staining intensity in Cd44−/−&Prg4GTR/GTR
synovia was lower than the corresponding mean inten-
sity in Cd44−/−&Prg4GT/GT synovia (p < 0.05). The ab-
sence of CD44 receptor increased PLOD2 staining in
synovial tissues as evidenced by a higher mean staining
intensity in Cd44−/−&Prg4GT/GT animals compared to
Cd44+/+&Prg4GT/GT animals (p < 0.001). In addition,
Prg4 re-expression reduced mean PLOD2 staining in
otherwise Cd44 null animals (p < 0.001).
Discussion
PRG4, also called lubricin and superficial zone protein,
is a mucinous glycoprotein with a protein core of 1404
amino acids and a central mucin domain that is exten-
sively glycosylated with O-linked β (1-3) Gal-GalNAc ol-
igosaccharides [29, 30, 50, 51]. PRG4 is secreted from
synovial fibroblasts and superficial zone chondrocytes
and is found adsorbed on articular surfaces and the syn-
ovial membrane in addition to its presence in SF [52,
53]. PRG4 has a multifaceted role in the joint and one
aspect of its role is to provide boundary lubrication, to
prevent friction-induced mitochondrial dysregulation
and chondrocyte apoptosis [54–56]. Synthesis of PRG4
by cartilage and synovium was reduced in posttraumatic
OA (PTOA) animal models and inflammatory cytokines,
e.g., IL-1β reduced PRG4 secretion by synovial fibro-
blasts while TGF-β produced an opposite effect [57–59].
Fig. 4 Stress fibers and focal adhesions (FAs) in murine synovial fibroblasts isolated from Prg4−/− and Prg4+/+ mice and their relationship to cell
migration. Stress fiber formation was probed using an anti-alpha smooth muscle actin (α-SMA) antibody (green). Vinculin (a marker of FAs)
expression was probed using an anti-vinculin antibody (green) and cells were counterstained using rhodamine-labeled phalloidin (cytoskeleton
label; red). The impact of rhPRG4 treatment (200 μg/mL) on basal Prg4−/− synovial fibroblast migration was assessed using the scratch assay and
the wound closure percentage was determined. To highlight the CD44-dependency of the enhanced basal migration of Prg4−/− synovial
fibroblasts, cells were also treated with either an anti-CD44 or isotype control (IC) antibodies (2 μg/mL for both antibodies). *p < 0.001; **p < 0.01;
n.s., non-significant. Scale in a = 50 μm (α-SMA) and 100 μm (vinculin); scale in c = 50 μm. a Representative images showing increased stress
fibers and FAs in Prg4−/− synoviocytes. b Prg4−/− synoviocytes demonstrated a higher mean FA size than Prg4+/+ synoviocytes. c Representative
images showing enhanced basal migration of Prg4−/− synoviocytes compared to Prg4+/+ synoviocytes. d rhPRG4 and anti-CD44 treatments were
equally effective in reducing basal migration of Prg4−/− synoviocytes
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Furthermore, SF PRG4 levels decreased following acute
joint trauma and in patients with advanced OA and
rheumatoid arthritis (RA) [60–62]. Therapeutically, na-
tive and rhPRG4 demonstrated disease-modifying activ-
ities in pre-clinical PTOA mediated by their ability to
reduce cartilage degeneration, enhance cartilage repair,
and reduce chondrocyte apoptosis [42, 63–65].
In this investigation, we studied rhPRG4’s antifibrotic
biological effects on fibroblasts in response to exogen-
ously introduced recombinant TGF-β or TGF-β pro-
duced by co-cultured macrophages in response to TLR4
receptor stimulation. We identified that PRG4 and HA
provide a similar outcome in TGF-β-stimulated OA FLS
in the form of preventing transition of fibroblasts to
myofibroblasts with inhibition of α-SMA expression and
thus stress fiber formation. PRG4 and HA produced an
antifibrotic effect in OA FLS using concentrations that
are well below what is normally found in SF [60–62]. As
HA is the prototypical CD44 ligand, we used HA as a
positive control and our findings support that CD44
modulates fibroblast to myofibroblast transition in OA
synoviocytes. PRG4 was rapidly internalized by OA FLS,
with a prominent role for CD44 in this process. How-
ever, CD44 was not the only mechanism by which OA
synoviocytes internalized rhPRG4 as approximately 60%
of rhPRG4 entry was blocked subsequent to CD44 re-
ceptor neutralization. CD44-mediated rhPRG4’s uptake
partially contributed to the latter’s antifibrotic role as
rhPRG4’s effect on α-SMA expression was significantly
weakened, but not completely abolished, when CD44-
mediated uptake was blocked. CD44 also played a role
in facilitating the enhanced migration of murine synovial
fibroblasts that lack Prg4 expression as antibody-
mediated neutralization of the receptor reduced cell
migration. This finding is consistent with our prior ob-
servation that Prg4 null synoviocytes had higher CD44
receptor expression levels compared to Prg4 competent
synoviocytes and is supported by an independent finding
that CD44 plays a role in facilitating cell migration [39,
66, 67]. Synovial fibrosis developed in Prg4 null mice
Fig. 5 Impact of co-culturing murine fibroblasts (F) and murine macrophages (M) on active and total supernatant TGF-β levels, fibroblast
migration, and efficacy of rhPRG4 in regulating fibroblast migration in the co-culture model. Murine macrophages (J774A) were stimulated with
lipopolysaccharide (LPS; 5 μg/mL) for 24 h prior to seeding in the top chamber of a co-culture system. Murine fibroblasts (NIH3T3) were cultured
in the lower chamber of the same system. Active and total TGF-β media levels were determined using an ELISA. A scratch was performed in the
fibroblast monolayer and fibroblast migration in the lower chamber was determined at 48 h ± rhPRG4 (200 μg/mL). *p < 0.001; **p < 0.01; n.s.,
non-significant. Scale = 40 μm. a Active and total TGF-β concentrations were higher in the fibroblast and macrophage co-culture compared to
fibroblasts alone. b Representative images of fibroblast migration across different experimental groups. Fibroblast migration was highest in co-
cultured fibroblasts and macrophages and rhPRG4 treatment reduced fibroblast migration. c rhPRG4 reduced fibroblast migration in a fibroblast
and macrophage co-culture model. d rhPRG4 did not alter active or total TGF-β media levels in the fibroblast and macrophage co-culture model
Qadri et al. Arthritis Research & Therapy          (2020) 22:113 Page 10 of 16
Fig. 6 Gene expression and immunohistological analysis of fibrotic markers: alpha smooth muscle actin (α-SMA) (ACTA2), collagen type-1 (COL1A1) and
procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD2) in synovial tissues isolated from 2- and 9-month-old gene-trap (Prg4GT/GT) and 2- and 9-month-old
recombined gene-trap (Prg4GTR/GTR) mice. The Prg4 gene-trap allele is a loss of function allele (Prg4GT/GT) whose function is restored with Cre-excision (Prg4GTR/GTR).
Recombination occurred at 3weeks of age using intraperitoneal tamoxifen (0.1mg/g in 100 μL corn oil vehicle) daily for 10 days. Fibrotic markers were probed
using specific antibodies and staining intensities (lumens per square millimeter) were quantified. *p< 0.001; **p< 0.01; ***p< 0.05. Scale = 100μm. a ACTA2
expression was higher in 9-month Prg4GT/GT compared to 2-month littermates and was reduced by Prg4 re-expression. b Representative images showing
enhanced α-SMA immunostaining in 2- and 9-month Prg4GT/GT synovia. c Prg4 re-expression reduced α-SMA content in 2- and 9-month-old animals. d COL1A1
expression was higher in 9-month-old Prg4GT/GT animals compared to 2-month and was reduced by Prg4 re-expression. e Representative images showing
enhanced collagen type-I immunostaining in 9-month-old Prg4GT/GT synovia. f Collagen type-I content was higher in 9-month-old Prg4GT/GT animals and was
reduced with Prg4 re-expression. g PLOD2 expression was higher in 9-month-old Prg4GT/GT animals compared to 2-month and was reduced by Prg4 re-
expression. h Representative images showing enhanced PLOD2 immunostaining in Prg4GT/GT synovia. i Prg4 re-expression reduced PLOD2 content in Prg4GT/GT
synovia in 2- and 9-month-old animals
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and the expression of SMA, PLOD2, and collagen type-I
progressively increased as animals aged. Interestingly,
the in vivo antifibrotic effect due to Prg4 re-expression
was not dependent on CD44 as endogenously produced
PRG4 reduced SMA and PLOD2 expression in Cd44
null animals.
CD44 is a single-pass transmembrane glycoprotein
that is widely expressed in immune and connective tis-
sues, and different isoforms, generated by alternate spli-
cing, have been characterized [66, 67]. The extracellular
domain of CD44 binds different ligands and thus can
sense a broad array of microenvironmental signals
resulting in ligand-specific effects in inflammation, cell
migration, and growth [67–69]. In addition to HA and
PRG4, other CD44 ligands include osteopontin, chon-
droitin, fibronectin, and matrix metalloproteinases
(MMPs) [69, 70]. The intracellular domain of CD44
lacks intrinsic kinase activity, but it transduces extracel-
lular ligand-specific signals via a combination of proteo-
lytic fragmentation or interactions with different
signaling pathways including members of Src and Ras
family of GTPases and protein phosphatase-2A [69, 71,
72]. HA is cellularly uptaken by CD44, and this inter-
action mediates HA’s ability to suppress MMP-13 and
aggrecanase-1 expression in OA chondrocytes and syno-
viocytes [73–75]. In addition to inhibiting synovitis, HA
treatment inhibited synovial fibrosis in a murine model
of TGF-β and treadmill running [75–77]. The effect of
HA was CD44-dependent as its antifibrotic effect was
abolished in CD44-deficient mice [77]. Contrary to HA,
PRG4 had an in vivo antifibrotic effect that was not
dependent on CD44. This might be related to PRG4’s
ability to regulate other signaling pathways apart from
CD44. PRG4 binds to and inhibits the activation of
TLR2 and TLR4 receptors by their ligands and by SF as-
pirates from patients with OA [78, 79]. In addition,
PRG4 was internalized by murine macrophages and co-
localized with both CD44 and TLR2 receptors in the
cytosol of these cells [80]. As such, it is expected that
the enhanced TLR2 and TLR4 receptor signaling in the
absence of PRG4 would propagate synovitis in Prg4 null
mice. The innate immune-mediated synovitis would in
turn contribute to the development of synovial fibrosis.
Upon Prg4 re-expression in 3-week-old animals, PRG4
would attenuate TLR2- and TLR4-mediated synovitis,
thereby potentially reducing TLR-regulated fibrotic tis-
sue remodeling [81].
Myofibroblasts are characterized by α-SMA expres-
sion, formation of stress fibers, and FAs and are thought
to play an effector role in the pathophysiology of tissue
fibrosis [81, 82]. Compared to fibroblasts, myofibroblasts
produce more collagen and respond to mitogenic signals
resulting in cell proliferation, migration, and secretion of
matrix-degrading enzymes [81, 83]. While stress fibers
Fig. 7 Modulation of expression of fibrotic markers: alpha smooth muscle actin (α-SMA) and procollagen-lysine, 2-oxoglutarate 5-dioxygenase
(PLOD2) in synovial tissues from Prg4 gene-trap animals by CD44. The Prg4 gene-trap allele is a loss of function allele (Prg4GT/GT) whose function is
restored with Cre-excision (Prg4GTR/GTR). Prg4GT/GT animals were crossed with Cd44−/− mice to generate PrgGT/GT&Cd44−/− animals. Recombination
occurred at 3 weeks of age using intraperitoneal tamoxifen (0.1 mg/g in 100 μL corn oil vehicle) daily for 10 days. Fibrotic markers were probed
using specific antibodies and staining intensities (lumens per square millimeter) were quantified. Prg4 recombination reduced α-SMA and PLOD2
staining in synovial tissues of 2-month-old Cd44+/+ and Cd44−/− animals. *p < 0.001; ***p < 0.05; n.s., non-significant
Qadri et al. Arthritis Research & Therapy          (2020) 22:113 Page 12 of 16
and FAs are unique structures within the cell, they are
highly interconnected, where they coordinate cell re-
sponses to mechanical signals in their microenvironment
[84]. Interestingly, the mean size of FAs, and not their
molecular composition or density, can accurately predict
cell migration [85]. Normal synovial fibroblasts do not
appear to express α-SMA, even with TGF-β stimulation
[86]. In our study, OA FLS had a basal level of α-SMA
expression and in response to TGF-β, α-SMA expression
was enhanced and stress fibers appeared. This was also
evident in murine NIH3T3 fibroblasts as the transition
from a fibroblast to a myofibroblast phenotype was ac-
companied by stress fiber and FAs formation, with sub-
cellular and cellular changes in the form of increased
number and mean size of FAs and cell spread area and
thus enhanced cell migration. rhPRG4 acted biologically
to reduce the formation of stress fibers and to reduce
the mean number and size of FAs in NIH3T3 fibroblasts
and this reduction resulted in arresting fibroblast migra-
tion. Thus, it is unlikely that the observed antimigratory
effect of rhPRG4 was a physical effect consequent to
PRG4’s amphipathic nature and its adsorption on hydro-
philic and hydrophobic surfaces [87]. The higher mean
size of FAs in synoviocytes from Prg4 null mice, and its
resultant enhanced migration argues that PRG4 plays a
role in regulating the expression of the cellular machin-
ery mediating migration in vivo. This may have bio-
logical relevance in the realm of synovial fibrosis where
PRG4 may function to reduce the migration of fibrocytes
to the inflamed joint and therefore the likelihood of add-
ing to the pool of existing myofibroblasts in the syno-
vium [88, 89].
Synovial tissue macrophages are critical regulators of
the initiation, maintenance, and resolution phases of
synovitis [90]. The complex functions of macrophages
are enabled by the presence of different macrophage
subpopulations within the joint, which fulfill distinct in-
flammatory and antiinflammatory roles [90]. In synovial
tissue fibrosis, bone marrow-derived monocytes and
macrophages are found in increased numbers, which
may signal their involvement in the development of syn-
ovial fibrosis [91, 92]. In response to an inflammatory
signal, macrophages produce TGF-β as a regulatory
feedback signal to aid in the resolution of inflammation
[93, 94]. TGF-β in turn triggers myofibroblast differenti-
ation and production of matrix proteins [38]. In our
study, LPS stimulation resulted in increased secretion of
TGF-β by macrophages. Cells secrete a latent form of
TGF-β, which in turn is proteolytically converted to ac-
tive TGF-β by a variety of proteases, including MMPs
[95]. The generation of active TGF-β in our co-culture
system was associated with fibroblast migration. Inter-
estingly, the introduction of rhPRG4 after macrophage
activation did not alter the total TGF-β quantity
produced by macrophages. Furthermore, rhPRG4 did
not alter the rate of activation of latent TGF-β, indicat-
ing that the antimigratory effect of rhPRG4 was at the
level of fibroblasts’ response to TGF-β receptor activa-
tion. This is supported by our observation that rhPRG4
reduced Smad3 phosphorylation in TGF-β reporter cells
and that reduction in pSmad3 intracellular levels attenu-
ated the TGF-β/Smad pathway activation. In TGF-β re-
porter cells, the attenuation of Smad signaling pathway
was downstream to rhPRG4 uptake by these cells in a
mechanism that involved CD44 receptor, similar to what
was observed in OA FLS. However, the precise mechan-
ism that is activated by CD44 engagement that inhibits
TGF-β/Smad signaling pathway remains unclear. An-
other limitation of our study was that we did not study
the antifibrotic effect of rhPRG4 in vivo.
Conclusion
In summary, we demonstrated that PRG4 is an import-
ant regulator of synovial tissue fibrosis using a combin-
ation of in vitro and in vivo models. PRG4 prevented the
transition of human and murine fibroblasts to a myofi-
broblast phenotype and in OA FLS; the mechanism of
PRG4’s antifibrotic effect was partially linked to CD44-
mediated cell uptake. rhPRG4 acted biologically to re-
duce Smad3 phosphorylation, the activation of TGF-β/
Smad signaling pathway, and FA mean size which trans-
lated to inhibiting fibroblast migration. The lack of Prg4
expression in murine synovial tissues resulted in en-
hanced expression of SMA, collagen type-I, and PLOD2,
the enzyme responsible for collagen cross-linking. Syn-
ovial fibrosis in Prg4GT/GT animals progressed with age
and re-establishing Prg4 expression was antifibrotic. The
role of PRG4 in regulating synovial fibrosis in vivo ex-
tends beyond its interaction with CD44 receptor, as Prg4
re-expression was antifibrotic in Cd44 null mice. Thera-
peutically, overexpressing PRG4 in the articular joint,
using a viral mediated gene delivery approach, may
prove beneficial in reducing synovial fibrosis in addition
to reducing cartilage degeneration [96, 97]. The study of
PRG4 as an antifibrotic modulator of the joint’s soft tis-
sues is further warranted especially with the known con-
tribution of synovial fibrosis in advanced OA.
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